Mylacand 8 mg, 16 mg Tablet
PDF Leaflet Revision Date: 19 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate hypertension and heart failure.
Dosage (summary)
Initial dose: 8 mg once daily; maintenance: 8-16 mg once daily; max: 32 mg. Heart failure: Initial 4 mg, titrate to 32 mg.
Onset of Action / Duration
Onset: 4 weeks, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not established in breastfeeding.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity
- Severe renal impairment
- Bilateral renal artery stenosis
- Severe hepatic impairment
- Pregnancy
Common side effects
- Hyperkalaemia
- Hypotension
- Renal impairment
- Dizziness
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Discontinue if pregnancy occurs
Serious warnings
- Risk of hypotension in heart failure patients
- Dual blockade of RAAS contraindicated
Important Disclaimer
The Mylacand 8 mg, 16 mg Tablet professional information leaflet below is the property of Viatris South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
